These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37849530)

  • 1. Synthesis and Optimization of 1-Substituted Imidazo[4,5-
    DeYoung EG; Howe JM; Fang S; Reddy MM; Handel JP; Gillen Miller JT; Wheeler DR; Tumey LN
    ACS Med Chem Lett; 2023 Oct; 14(10):1358-1368. PubMed ID: 37849530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Characterization of Immune-Stimulating Imidazo[4,5-c]quinoline Antibody-Drug Conjugates.
    Fang S; Brems BM; Olawode EO; Miller JT; Brooks TA; Tumey LN
    Mol Pharm; 2022 Sep; 19(9):3228-3241. PubMed ID: 35904247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Toll-like receptor 7 agonists with novel chromeno[3,4-d]imidazol-4(1H)-one and 2-(trifluoromethyl)quinoline/ quinazoline-4-amine scaffolds.
    Dolšak A; Švajger U; Lešnik S; Konc J; Gobec S; Sova M
    Eur J Med Chem; 2019 Oct; 179():109-122. PubMed ID: 31247373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular dynamics simulations reveal the selectivity mechanism of structurally similar agonists to TLR7 and TLR8.
    Wang X; Chen Y; Zhang S; Deng JN
    PLoS One; 2022; 17(4):e0260565. PubMed ID: 35452465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.
    Larson P; Kucaba TA; Xiong Z; Olin M; Griffith TS; Ferguson DM
    ACS Med Chem Lett; 2017 Nov; 8(11):1148-1152. PubMed ID: 29152046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel and Selective TLR7 Antagonists among the Imidazo[1,2-
    Bou Karroum N; Moarbess G; Guichou JF; Bonnet PA; Patinote C; Bouharoun-Tayoun H; Chamat S; Cuq P; Diab-Assaf M; Kassab I; Deleuze-Masquefa C
    J Med Chem; 2019 Aug; 62(15):7015-7031. PubMed ID: 31283223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Synthesis of Polyphenolic Imidazo[4,5-
    Kumar K; Sihag B; Patil MT; Singh R; Sakala IG; Honda-Okubo Y; Singh KN; Petrovsky N; Salunke DB
    ACS Pharmacol Transl Sci; 2024 Jul; 7(7):2063-2079. PubMed ID: 39022355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor for Treatment of Autoimmunity.
    Vlach J; Bender AT; Przetak M; Pereira A; Deshpande A; Johnson TL; Reissig S; Tzvetkov E; Musil D; Morse NT; Haselmayer P; Zimmerli SC; Okitsu SL; Walsky RL; Sherer B
    J Pharmacol Exp Ther; 2021 Mar; 376(3):397-409. PubMed ID: 33328334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.
    Beesu M; Salyer AC; Brush MJ; Trautman KL; Hill JK; David SA
    J Med Chem; 2017 Mar; 60(5):2084-2098. PubMed ID: 28146629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll-like receptor 7 and 8 imidazoquinoline-based agonist/antagonist pairs.
    Yang M; Larson PG; Brown L; Schultz JR; Kucaba TA; Griffith TS; Ferguson DM
    Bioorg Med Chem Lett; 2022 Mar; 59():128548. PubMed ID: 35051578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic Toll-like Receptors 7 and 8 Agonists: Structure-Activity Relationship in the Oxoadenine Series.
    Evans JT; Bess LS; Mwakwari SC; Livesay MT; Li Y; Cybulski V; Johnson DA; Bazin HG
    ACS Omega; 2019 Sep; 4(13):15665-15677. PubMed ID: 31572869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant.
    Kaushik D; Dhingra S; Patil MT; Piplani S; Khanna V; Honda-Okubo Y; Li L; Fung J; Sakala IG; Salunke DB; Petrovsky N
    Hum Vaccin Immunother; 2020 Aug; 16(8):1989-1996. PubMed ID: 32298200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR7/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7.
    Lai CY; Liu YL; Yu GY; Maa MC; Leu TH; Xu C; Luo Y; Xiang R; Chuang TH
    Vaccine; 2014 Sep; 32(43):5593-9. PubMed ID: 25131730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.
    Gorden KB; Gorski KS; Gibson SJ; Kedl RM; Kieper WC; Qiu X; Tomai MA; Alkan SS; Vasilakos JP
    J Immunol; 2005 Feb; 174(3):1259-68. PubMed ID: 15661881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies.
    Lan T; Dai M; Wang D; Zhu FG; Kandimalla ER; Agrawal S
    J Med Chem; 2009 Nov; 52(21):6871-9. PubMed ID: 19824640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-Assembled TLR7/8 Agonist-Mannose Conjugate as An Effective Vaccine Adjuvant for SARS-CoV-2 RBD Trimer.
    Teng C; Meng X; Hu Y; Mao H; Li H; Yang J; Sun T; Meng S; Zong C
    Polymers (Basel); 2022 Dec; 14(24):. PubMed ID: 36559833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of potent, orally bioavailable in vivo efficacious antagonists of the TLR7/8 pathway.
    Alper PB; Deane J; Betschart C; Buffet D; Collignon Zipfel G; Gordon P; Hampton J; Hawtin S; Ibanez M; Jiang T; Junt T; Knoepfel T; Liu B; Maginnis J; McKeever U; Michellys PY; Mutnick D; Nayak B; Niwa S; Richmond W; Rush JS; Syka P; Zhang Y; Zhu X
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127366. PubMed ID: 32738975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an
    Betschart C; Faller M; Zink F; Hemmig R; Blank J; Vangrevelinghe E; Bourrel M; Glatthar R; Behnke D; Barker K; Heizmann A; Angst D; Nimsgern P; Jacquier S; Junt T; Zipfel G; Ruzzante G; Loetscher P; Limonta S; Hawtin S; Andre CB; Boulay T; Feifel R; Knoepfel T
    ACS Med Chem Lett; 2022 Apr; 13(4):658-664. PubMed ID: 35450354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accessory-cell-mediated activation of porcine NK cells by toll-like receptor 7 (TLR7) and TLR8 agonists.
    Toka FN; Nfon CK; Dawson H; Golde WT
    Clin Vaccine Immunol; 2009 Jun; 16(6):866-78. PubMed ID: 19369481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.
    Wang D; Precopio M; Lan T; Yu D; Tang JX; Kandimalla ER; Agrawal S
    Mol Cancer Ther; 2010 Jun; 9(6):1788-97. PubMed ID: 20515950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.